Introduction {#s1}
============

Under conditions of reduced fluid volume and in response to stress, the kidneys release renin, which cleaves angiotensinogen to angiotensin I (Ang I) ([@CIT0034]). Ang I is subsequently converted to Ang II by the peptidase angiotensin-converting enzyme (ACE). Ang II, the major mediator of the renin-angiotensin system (RAS), stimulates type-1 Ang II (AT1) receptors. Stimulation of AT1 receptors in the hypothalamic-pituitary-adrenal (HPA) axis regulates the stress response by increasing circulating levels of glucocorticoids and catecholamines, which in turn act in a negative feedback cycle to dampen HPA axis activation.

In addition to the HPA axis, AT1 receptors are also expressed in the striatum ([@CIT0004], [@CIT0005]; [@CIT0016]), a key part of the mesocorticolimbic system implicated in the development of substance use disorders ([@CIT0040]). Indeed, both stimulation of AT1 receptors ([@CIT0003]) and drugs of abuse ([@CIT0045]; [@CIT0007]; [@CIT0012]) potently increase the release of catecholamines (i.e., dopamine \[DA\] and norepinephrine \[NE\]) in the nucleus accumbens and mesocorticolimbic system. For example, cocaine (and probably other drugs of abuse) significantly increases ACE activity and mRNA expression in frontal cortex and striatum ([@CIT0042]). Moreover, Ang II potentiates stimulant-induced increases of NE ([@CIT0028]), and this is attenuated by ACE inhibition ([@CIT0039]). Similarly, genetic mouse models show that overexpression of angiotensinogen significantly increases voluntary consumption of alcohol, whereas genetically ablating angiotensinogen has the opposite effect ([@CIT0026]). Consistent with the latter, ACE inhibitors reduce alcohol consumption ([@CIT0023]) and morphine self-administration ([@CIT0015]) in rodent models. Collectively, biochemical and behavioral evidence strongly implicate central RAS involvement in neural substrates and neurotransmitter systems known to mediate the actions of abused drugs ([@CIT0022]). In addition to substance use disorders, the central RAS is also implicated in other neuropsychiatric/neurological disorders, including schizophrenia ([@CIT0019]), Alzheimer's disease ([@CIT0009]), and Parkinson's disease ([@CIT0027]).

Although the effects of methamphetamine (METH) are mediated chiefly by direct facilitation of DA and NE signaling, METH also alters function of the HPA axis, which likely contributes to the overall effects produced by METH. Because AT1 receptors regulate the HPA axis, blocking the effects of METH on the central RAS could potentially attenuate the effects produced by METH. With this in mind, we previously conducted a double-blind, placebo-controlled, inpatient human laboratory-based study to determine the impact of perindopril treatment (0, 2, 4, or 8mg/d) on the subjective effects produced by acute i.v. METH (30mg) in participants (n*=*30) with METH use disorder ([@CIT0030]). Consistent with the idea that blocking the effects of METH on the central RAS might attenuate the effects produced by METH, our previous study found a significant treatment by METH interaction on the subjective ratings of "any drug effect"; however, posthoc tests did not reveal significant differences between groups, most likely due to small group sizes. Thus, the present study was undertaken to replicate and extend these findings to determine whether similar (4 or 8mg/d) or a higher (16mg/d) dose of perindopril would attenuate the subjective effects produced by i.v. METH in volunteers with METH use disorder.

Methods {#s2}
=======

This double-blind, placebo-controlled study was sponsored by the National Institute on Drug Abuse and approved by the Baylor College of Medicine and Michael E. DeBakey Veteran Affairs Medical Center (MEDVAMC) Institutional Review Boards. Also, this material is the result of work supported with resources from, and the use of facilities at, the MEDVAMC, Houston, TX. All volunteers provided written informed consent after being apprised of potential risks of study participation.

Subjects {#s3}
--------

All participants were non-treatment-seeking, English-speaking volunteers recruited through advertisements, paid for their participation, and met the DSM-IV-TR criteria for METH dependence. DSM-IV-TR diagnosis criteria for substance dependence has been shown to correlate with DSM5 diagnostic criteria for use disorders. Therefore, we use DSM5 nomenclature throughout this manuscript ([@CIT0006]). All participants were between 18 and 55 years old with a history of using METH by the smoked or i.v. route. Participants were required to provide a urine sample that was positive for METH but negative for other illicit drugs, except marijuana. In addition, participants were required to provide a medical history and undergo a brief physical examination to ensure they did not have clinically significant contraindications before study participation. Thus, potential participants were excluded if they had a history of seizure disorder, head trauma, dependence on other drugs aside from nicotine, prior adverse reactions to METH, or the presence of any other axis I psychiatric disorder. Serious medical conditions such as heart disease, symptomatic HIV-related disease, asthma, and other serious medical conditions were also exclusionary. Concomitant use of psychotropic medications was not allowed aside from low-dose benzodiazepine (lorazepam, 2mg) for sleep.

General Procedures {#s4}
------------------

A timeline of study events, including METH and perindopril administrations, are provided in [Figure 1](#F1){ref-type="fig"}. Briefly, following admission on day 0, participants resided at the Research Commons of the MEDVAMC for the duration of this 10-day double-blind study. Before (day 1) and after (day 6 or 8) treatment, cardiovascular and subjective effects in response to 30mg METH were determined for each participant. On day 10, medication was discontinued, and participants were discharged from the study.

![Timeline of study events, including methamphetamine (METH) and perindopril dosing.](ijnppy_pyw029_f0001){#F1}

METH {#s5}
====

A NIDA contractor (RTI International, Research Triangle Park, NC) provided sterile METH solution for human use, and a saline solution of equal volume and appearance served as the control. Single bolus infusions of 15 and 30mg METH were used as in our previous studies, since they consistently produce significant increases in positive subjective effects ([@CIT0030]; [@CIT0007]; [@CIT0041]). METH was infused over 2 minutes by a study physician on days 1, 6, and 8. Within each day, METH infusions were randomized to either 10:00 [am]{.smallcaps} or 1:00 [pm]{.smallcaps} by the VA pharmacy; at the alternate times (i.e., 10 AM or 1 PM), saline (0mg METH) was infused. The first 30-mg dose of METH was infused on day 1 before treatment randomization. The second (and final) infusion of 30mg METH was randomized to either day 6 or 8 by the VA pharmacy; on the alternate day (i.e., day 6 or 8), the 15-mg dose of METH was infused to maintain the blind. Thus, if a participant received the second, 30-mg dose of METH on day 6, that same participant received the 15-mg dose of METH on day 8 or vice versa.

Subjective Ratings and Cardiovascular Effects of METH {#s6}
-----------------------------------------------------

Participants completed visual analog scale forms to rate the subjective effects produced by METH 15 minutes before and 5, 10, 15, 20, 30, 45, 60, 75, 90, 105, and 120 minutes after every infusion. Visual analog scale subjective ratings, which were measured on a continuous scale digitized between 0 (not at all) to 100 (strongest ever), included ratings of anxious, any drug effect, bad effects, depressed, desire (for METH), drug liking, good effects, high, likely to use (METH if accessible), and stimulated. Cardiovascular (i.e., heart rate and blood pressure \[BP\]) measures were collected at the same time points subjective ratings were collected.

Perindopril {#s7}
-----------

Placebo and commercially available perindopril tablets were overencapsulated in gelatin capsules by the MEDVAMC research pharmacy. Two perindopril or matched placebo capsules were administered orally at 7:00 [am]{.smallcaps} beginning on day 2 and continuing through day 10 of the protocol.

Data Analysis {#s8}
-------------

Demographic and baseline drug use characteristics were compared using chi-square tests and ANOVA for categorical and continuous variables, respectively. To simplify analyses of subjective ratings and cardiovascular measures, 2-factor \[METH (dose): 0 and 30mg, or 0, 15, and 30mg; and treatment (dose): 0, 4, 8, and 16 mg\] ANOVAs were calculated on maximum or peak ratings/measures to determine: (1) whether or not participants responded differentially to METH (0 and 30mg) prior to perindopril maintenance; and (2) treatment effects after perindopril maintenance. Significant main effects were interpreted with Bonferroni-corrected posthoc tests. Data are presented as means ± SD, except as displayed in illustrations where data are presented as means ± SEs.

Results {#s9}
=======

Participants {#s10}
------------

Sixty participants were randomized to medication conditions (placebo \[n=17\], 4mg perindopril \[n=14\], 8mg perindopril \[n=16\], and 16mg perindopril \[n=13\]). Posttreatment data were missing for 1 participant because of a technicality; thus, analyses were conducted on the 59 participants for whom there was a complete set of data. The flow of participants is shown in [Figure 2](#F2){ref-type="fig"}.

![Participant flow, including the number of participants assessed for eligibility, randomized to a treatment group, and analyzed for the placebo (0mg; n=17) and 4-mg (n=14), 8-mg (n=16) and 16-mg (n=12) perindopril treatment groups.](ijnppy_pyw029_f0002){#F2}

Demographics {#s11}
------------

On average, the 59 participants for whom we had complete data were 36 (±1.2) years old, Caucasian (76%), and male (78%) with 12.4 (±0.3) years of education. The majority of participants usually used METH via multiple routes, although all participants reported previously having used METH by the i.v. or smoked routes. On average, participants reported using METH at 0.9 (±0.1) g/d and reported using it on 16 (±1.2) of the last 30 days. Demographic and drug use means for each group are provided in [Table 1](#T1){ref-type="table"}.

###### 

Demographic and Drug Use Characteristics

                           Treatment Groups   Analyses                                                                             
  ------------------------ ------------------ ----------- ----------- ----------- --------------- ---------------- --------------- ------
  Demographics             Sex                Male        13          9           13              11               \(3\) = 2.96    .398
  Female                   4                  5           3           1                                                            
  Race                     African American   1           1           2           0               \(12\) = 11.28   .506            
  Asian                    2                  0           1           0                                                            
  Caucasian                13                 10          12          10                                                           
  Hispanic                 0                  3           1           2                                                            
  Middle Eastern           1                  0           0           0                                                            
  Other                    Age                39.4±9.1    33.3±8.9    36.0±8.8    34.3±9.1        (3,55) = 1.40    .253            
  Education (y\>)          12.2±2.6           12.4±1.7    12.0±1.3    13.0±2.7    (3,55) = 0.60   .617                             
  Methamphetamine          Use                Years       15.4±9.7    11.1±6.6    11.5±10.3       13.8±9.0         (3,55) = 0.76   .520
  Past 30 days             15.5±10.1          15.7±11.2   16.9±7.0    16.0±9.6    (3,55) = 0.07   .974                             
  g/d                      1.2±0.8            0.8±0.5     0.9±0.5     0.8±0.2     (3,49) = 1.55   .215                             
  Routes Used              IV                 12          7           10          8               \(9\) = 12.25    .200            
  Smoke                    14                 10          12          9           \(3\) = 0.55    .907                             
  Oral                     4                  4           8           4           \(6\) = 6.97    .323                             
  Nasal                    1                  0           4           2           \(3\) = 5.37    .147                             
  Nicotine                 Current users      15          11          14          11              \(3\) = 1.08     .782            
  Years\*                  20.3±11.3          16.5±8.1    19.5±11.1   17.2±9.8    (3,47) = 0.38   .767                             
  Cigarettes per day\*     14.2±7.7           15.1±5.9    15.3±5.1    13.8±8.0    (3,47) = 0.15   .931                             
  Alcohol                  Current users      7           6           12          4               \(3\) = 6.13     .105            
  Years\*                  20.4±13.1          13.5±9.9    18.8±9.6    17.3±13.9   (3,25) = 0.46   .710                             
  Days used of past 30\*   8.9±7.1            4.3±5.3     6.0±8.1     8.0±7.8     (3,25) = 0.50   .687                             
  Drinks per day\*         3.6±3.4            2.0±1.1     2.0±1.3     1.4±0.8     (3,25) = 1.40   .266                             
  Cannabis                 Current users      11          6           9           7               \(3\) = 1.53     .675            
  Years\*                  14.0±9.4           16.5±10.4   23.3±44.8   12.6±12.2   (3,29) = 1.67   .194                             
  Days used of past 30\*   12.1±11.8          7.0±11.5    13.1±12.7   9.2±10.5    (3,29) = 0.41   .745                             
  Times per day\*          3.7±3.3            2.4±1.7     1.8±1.1     2.1±1.4     (3,29) = 1.48   .242                             

\*Data reflect current users only. Data are presented as means ± SDs.

Tolerability {#s12}
------------

Participants generally tolerated perindopril treatment well. There were no significant (F~(3,\ 55)~=.33; *P*=0.806) differences across groups for total number (n=88) of reported complaints or abnormal laboratory findings (adverse events). The most common complaints included headache (n=31; *P*=.988) and gastrointestinal distress (n=21; *P*=0.175), which are not common side effects of perindopril. There were no significant (F~(3,\ 55)~= 0.63; *P=*.6002) differences across groups for total number (n=26) of lorazepam doses administered, which were prescribed to 35% (n=6), 57% (n=8), 38% (n=6), and 50% (n=6) of participants in the placebo and 4-, 8-, and 16-mg treatment groups.

Pretreatment {#s13}
------------

### Subjective {#s14}

Importantly, prior to perindopril maintenance there were nonsignificant (*P*≥.2383) treatment by METH interactions and nonsignificant (*P*≥.0977) main effects of treatment on all subjective ratings. Analyses also revealed nonsignificant (*P*≥.0751) main effects of METH on ratings of anxious, depressed, desire, and likely to use. In contrast, there were significant main effects of METH on ratings of any drug effect (F~(1,\ 110)~=49.45; *P*\<.0001), bad effects (F~(1,\ 110)~=6.40; *P*=.0128), drug liking (F~(1,\ 110)~=25.10; *P*\<.0001), good effects (F~(1,\ 110)~=35.78; *P*\<.0001), high (F~(1,\ 110)~ =48.38; *P*\<.0001), and stimulated (F~(1,\ 110)~=44.03; *P*\<.0001).

### Cardiovascular {#s15}

Similar to subjective ratings, there were nonsignificant (*P*≥.5491) treatment by METH interactions as well as nonsignificant (*P*≥.1000) main effects of treatment on all cardiovascular measures. In contrast, there were significant main effects of METH on heart rate (F~(1,\ 110)~=21.19; *P*\<.0001), systolic BP (F~(1,\ 110)~=43.62; *P*\<.0001), and diastolic BP (F~(1,\ 110)~=12.46; *P*=.0006).

Posttreatment {#s16}
-------------

### Subjective {#s17}

Following 5 to 7 days of perindopril maintenance, analyses revealed nonsignificant (*P*≥.2343) treatment by METH interactions on all subjective ratings. There were also nonsignificant main effects of both treatment (*P*≥.0851) and METH (*P*≥.2665) on ratings of depressed, desire, and likely to use. There were significant main effects of METH (*P*≤.0114) on all remaining ratings. Bonferroni-corrected posthoc tests revealed that compared with placebo METH ratings of bad effects, ratings were significantly (*P*=.0085) higher for the 30-mg METH dose only. For all other ratings, Bonferroni-corrected posthoc tests revealed that compared with placebo METH, ratings were significantly higher for the 15- (*P*≤.0161) and 30- (*P*≤.0014) mg METH doses.

In contrast to pretreatment analyses, posttreatment analyses revealed a significant main effect of treatment (F~(3,\ 224)~=5.13; *P*=.0019) on anxious ratings. As illustrated in [Figure 3](#F3){ref-type="fig"}, Bonferroni-corrected posthoc tests revealed that compared with placebo treatment ratings (23.53±30.16), ratings were significantly (*P*=.0009) lower for the 8-mg treatment dose (9.53±16.18) and nonsignificantly (*P*≥.0490) lower for the 4- (15.00±24.12) and 16- (21.67±24.35) mg treatment doses.

![Posttreatment mean ratings of anxious across methamphetamine (METH) doses (0, 15, and 30mg). Comparisons across treatment doses revealed a significant (*P*=.0019) main effect of treatment dose. The asterisk (\*) indicates that anxious ratings were significantly (*P*=.0009) lower in the 8-mg treatment group compared with the placebo treatment group. Data are presented as means ± SEs for the 0-mg (n=17), 4-mg (n=14), 8-mg (n=16), and 16-mg (n=12) perindopril groups.](ijnppy_pyw029_f0003){#F3}

There was a significant main effect of treatment (F~(3,\ 224)~=8.63; *P*\<.0001) on stimulated ratings. As illustrated in [Figure 4](#F4){ref-type="fig"}, posthoc tests revealed that compared with placebo treatment ratings (25.15±30.59), ratings were significantly (*P*=.0070) lower for the 8-mg treatment dose (13.91±22.30) and nonsignificantly (*P*≥.0254) higher for the 4- (25.89±30.32) and 16- (35.21±32.62) mg treatment doses.

![Posttreatment mean ratings of stimulated across methamphetamine (METH) doses (0, 15, and 30mg). Comparisons across treatment doses revealed a significant (*P*\<.0001) main effect of treatment dose. The asterisk (\*) indicates that stimulated ratings were significantly (*P*=.0070) lower in the 8-mg treatment group compared with the placebo treatment group. Data are presented as means ± SEs for the 0-mg (n=17), 4-mg (n=14), 8-mg (n=16), and 16-mg (n=12) perindopril groups.](ijnppy_pyw029_f0004){#F4}

There were significant main effects of treatment on ratings of any drug effect (*P*=.0026), bad effects (*P*=.0003), drug liking (*P*=.0489), good effects (*P*=.0026), and high (*P*=.0026); Bonferroni-corrected posthoc tests revealed, however, that there were nonsignificant rating differences for the 4- (*P*≥.0352), 8- (*P*≥.0240), and 16- (*P*≥.0250) mg treatment doses compared with placebo treatment.

### Cardiovascular {#s18}

Similar to pretreatment cardiovascular effects, there were nonsignificant (*P*≥.5015) treatment by METH interactions, as well as nonsignificant (*P*≥.1899) main effects of treatment, on all cardiovascular measures. In contrast, there were significant (*P*\<.0001) main effects of METH on all cardiovascular measures. Bonferroni-corrected posthoc tests revealed that compared with placebo METH, cardiovascular effects were significantly greater for the 15- (*P*\<.0043) and 30- (*P*\<.0001) mg METH doses. For systolic BP, there was also a significant (*P*=.0008) difference between the 15- and 30-mg METH doses.

Discussion {#s19}
==========

This double-blind, placebo-controlled human laboratory study assessed the impact of perindopril treatment on cardiovascular and subjective effects produced by i.v. METH administration in non-treatment-seeking volunteers with METH use disorder. As expected, METH (15 and 30mg) alone increased cardiovascular measures and positive subjective ratings. The most consistent treatment effects on subjective ratings were observed in the 8-mg perindopril group. Specifically, compared to treatment with placebo, treatment with 8mg perindopril significantly reduced METH-induced increases on ratings of anxious and stimulated, and nonsignificantly reduced ratings of any drug effect, good effects, high, and drug liking. Interestingly, as the dose of perindopril increased, however, the response decreased. Thus, while treatment with 8mg perindopril decreased positive subjective ratings produced by METH, treatment with 16mg perindopril tended to increase these same subjective ratings.

The current results are somewhat consistent with our previous report ([@CIT0030]), in which the effect of perindopril on METH-induced subjective effects did not follow a classic dose-response function. On the other hand and in contrast to the current findings, [@CIT0030] previously found that the effects produced by METH were nonsignificantly higher in the 8- vs 4-mg perindopril dose. Nonetheless, there are notable differences between the 2 studies. First, while the current analyses were conducted on peak subjective ratings across 2-hour intervals, our previous report analyzed subjective ratings at only the 30-minute time point. The previous report also analyzed the mean change in ratings; that is, ratings at baseline or the 0-minute time point were subtracted from ratings at the 30-minute time point prior to analyses. The current study also had nearly twice the number of participants in each group. In addition, there could be other factors that underlie, at least in part, the discrepant findings between these studies. For example, given the nonlinear effects of perindopril observed in both studies, it could be that the weight-based dose (i.e., mg/kg) of perindopril between the 2 studies differed, which would produce a shift in the dose-response curve. On the other hand, genetic variations ([@CIT0044]) and diuretics (e.g., caffeine) are also known to affect the RAS; consequently, between-group differences in either of these factors could also have affected therapeutic responses.

The biological mechanism(s) underlying the nonlinear effects of perindopril on METH-induced subjective effects are likely complex, because ACE inhibitors modulate a variety of peptides. For example, in addition to reducing Ang II synthesis, ACE inhibitors also slow the metabolism of substance P ([@CIT0014]; [@CIT0047]; [@CIT0037]; [@CIT0048]) and increase striatal pre-proenkephalin mRNA levels ([@CIT0018]). Substance P is a neurokinin-1 receptor agonist, and they prevent stimulant-induced increases in striatal DA ([@CIT0024]). Enkephalins tonically modulate DA release, and inhibiting their degradation increases striatal DA release ([@CIT0008]), which is consistent with the ability of ACE inhibitors to increase DA release in rat striatum (Jenkins et al., 1997; Mendelsohn et al., 1993). These results are compatible with perindopril increasing striatal DA function. Increased striatal DA responsiveness would be expected to enhance the positive subjective effects produced by METH, at least in principle, because it would be the equivalent of administering higher doses. Nonetheless, those significant effects were most consistently observed with moderate doses of perindopril, which is consistent with the efficacy of 2mg/kg/d perindopril, but not 1 or 4mg/kg/d, to increase antioxidant levels in rodent hippocampus ([@CIT0025]) as well as with 4 and 8mg/d perindopril, but not 16mg/d, to decrease circulating levels of ANG II in normotensive men ([@CIT0043]). It could be that larger doses of perindopril progressively inhibit ACE in more brain regions in humans, as has been shown in rodents ([@CIT0036]), thereby altering the subjective effects of METH.

The effects of ACE inhibitors in the brain are even more complex when the role of Ang II is considered. In addition to stimulating AT1 receptors, Ang II also stimulates AT2 receptors. While the function of AT2 receptors in the brain is not well defined, AT1 receptor expression in the nucleus accumbens ([@CIT0017]) and locus coeruleus ([@CIT0020]), as well as modulatory effects of AT1 receptors on NE ([@CIT0010]), serotonin ([@CIT0029]), glutamate, and GABA ([@CIT0002]; [@CIT0031]) neurotransmission, have all been described. Considering that AT1 receptor blockade attenuates the release of stress hormones ([@CIT0001]) and measures of anxiety ([@CIT0035]) suggests at least some effects of ACE inhibitors are mediated via the AT1 receptor. Consistent with this, AT1 receptor blockade attenuates the development of amphetamine-induced behavioral sensitization ([@CIT0032]) and amphetamine induces persistent alterations of AT1 receptor expression in the nucleus accumbens and caudate putamen of rodents ([@CIT0033]). These studies suggest that selectively blocking the AT1 receptor in humans may more effectively reduce the acute subjective effects produced by METH compared with the ability of perindopril in the current study. In fact, our preliminary (C. N. Haile, C. D. Verrico, and T. F. Newton, unpublished observations) data indicate that the AT1 receptor antagonist candesartan attenuates METH- and cocaine-induced cravings, supporting this idea.

Regardless of the underlying mechanism(s) by which perindopril modulates the subjective effects of METH, it is also noteworthy that ACE inhibitors decrease depression in hypertensive patients ([@CIT0011]) and the release of stress hormones in healthy controls ([@CIT0049]), which could play a role in reducing stress-related relapse to METH use. This idea is consistent with the current findings; all active perindopril doses reduced anxious ratings ([Figure 3](#F3){ref-type="fig"}). ACE inhibitors have also been reported to decrease the incidence of cognitive impairment in humans ([@CIT0046]) and protect against dopaminergic neurotoxicity in animal models of Parkinson's disease ([@CIT0038]).

Collectively, the anxiolytic-, antidepressant-, and cognitive-enhancing properties of ACE inhibitors, coupled with their cardio- and neuro-protective qualities, suggest that ACE inhibitors may have some clinical utility for individuals who use METH. On the other hand, numerous factors affect therapeutic responses to perindopril. AT1 receptor blockers confer many of the same benefits as ACE inhibitors, but they do not directly inhibit ACE activity or inhibit the breakdown of bradykinin. Thus, while perindopril might not be an ideal treatment for METH use disorder, the current findings suggest that downstream components of the RAS might provide a more consistent and effective therapeutic target for reducing the effects produced by METH.
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